Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Zanaboni

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Haematologica|July 5, 2006
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overloadAntonio Piga, Renzo Galanello, Gian Luca Forni, et al.
Haematologica|December 31, 2016
Plerixafor and G-CSF combination mobilizes hematopoietic stem and progenitors cells with a distinct transcriptional profile and a reduced <i>in vivo</i> homing capacity compared to plerixafor aloneMaria Rosa Lidonnici, Annamaria Aprile, Marta Claudia Frittoli, et al.
Endocrine|January 31, 2016
Bone turnover and mineral density in adult thalassemic patients: relationships with growth hormone secretory status and circulating somatomedinsMassimo Scacchi, Leila Danesi, Agnese Cattaneo, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Haematologica|July 5, 2006
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overloadAntonio Piga, Renzo Galanello, Gian Luca Forni, et al.
Haematologica|December 31, 2016
Plerixafor and G-CSF combination mobilizes hematopoietic stem and progenitors cells with a distinct transcriptional profile and a reduced <i>in vivo</i> homing capacity compared to plerixafor aloneMaria Rosa Lidonnici, Annamaria Aprile, Marta Claudia Frittoli, et al.
Endocrine|January 31, 2016
Bone turnover and mineral density in adult thalassemic patients: relationships with growth hormone secretory status and circulating somatomedinsMassimo Scacchi, Leila Danesi, Agnese Cattaneo, et al.
Pageof 2